Skip to content

Mulberry leaf tea reduces atherosclerotic lesions in patients with coronary heart disease via 1-Deoxynojirimycin

Mulberry leaf tea reduces atherosclerotic lesions in patients with coronary heart disease via 1-Deoxynojirimycin

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035222
Enrollment
Unknown
Registered
2020-08-04
Start date
2018-07-27
Completion date
Unknown
Last updated
2020-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

control and intervention groups:Bulberry leaf tea

Sponsors

The First Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: CHD was diagnosed with the criteria for CHD. Coronary angiography or coronary CTA confirmed that the main branch lumen diameter of at least one vessel was more than 50% or that there was a clear ST segment elevation or non-ST segment; The patients had evidence of elevated myocardial infarction and the patients were with informed consent. The patients were diagnosed with dyslipidemia (LDL-C >=140 mg/dL, Triglyceride (TG) >=150 mg/dL or HDL-C more than 3 months, and percutaneous coronary intervention (PCI) > 10 months. The patients had mild or moderate heart failure (New York Heart Association (NYHA) Functional Classification I or II).

Exclusion criteria

Exclusion criteria: The patients had the following status: severe hepatic and renal dysfunction (aspartate transaminase (AST) more than 100 IU/L, alanine transaminase (ALT) more than 100 IU/L, serum creatinine more than 1.5 mg/dL) within one month; ongoing treatment with DNJ more than one month; ongoing treatment with cyclosporine; allergic to DNJ or the drugs used in the present study; total glycerol (TG) level more than 400 mg/dL; HbA1c (Hemoglobin A1c) level more than 8%; and pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
blood lipid;

Countries

China

Contacts

Public ContactWang Yuting

The First Hospital of Jilin University

wangyutingjl@126.com+86 15943022060

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026